Juan Flores-Montero

List of Publications by Year
in descending order

58 papers	4,110 citations	201575 27 h-index	149623 56 g-index
58 all docs	58 docs citations	58 times ranked	4268 citing authors

#	Article	IF	Citations
1	EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia, 2012, 26, 1908-1975.	3.3	738
2	EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia, 2012, 26, 1986-2010.	3.3	668
3	Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia, 2017, 31, 2094-2103.	3.3	486
4	Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for <scp>MRD</scp> detection in multiple myeloma. Cytometry Part B - Clinical Cytometry, 2016, 90, 61-72.	0.7	177
5	Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. Journal of Clinical Oncology, 2020, 38, 784-792.	0.8	175
6	Quality assessment program for <scp>E</scp>uro<scp>F</scp>low protocols: Summary results of fourâ€year (2010â€“2013) quality assurance rounds. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 145-156.	1.1	144
7	Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping. Leukemia, 2010, 24, 1927-1933.	3.3	131
8	Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood, 2016, 127, 3165-3174.	0.6	129
9	The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia, 2008, 22, 1175-1183.	3.3	114
10	MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. Blood Advances, 2017, 1, 728-732.	2.5	84
11	Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood, 2021, 137, 49-60.	0.6	80
12	Flow cytometric immunobead assay for the detection of BCRâ€“ABL fusion proteins in leukemia patients. Leukemia, 2009, 23, 1106-1117.	3.3	75
13	Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer Journal, 2018, 8, 117.	2.8	74
14	Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood, 2019, 134, 2218-2222.	0.6	66
15	A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic Bâ€cell chronic lymphoproliferative disorders. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 1141-1150.	1.1	60
16	Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer Journal, 2020, 10, 108.	2.8	60
17	Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: A pilot study on a series of 56 patients. Cytometry Part B - Clinical Cytometry, 2010, 78B, 154-168.	0.7	53
18	Utility of <scp>CD</scp>54, <scp>CD</scp>229, and <scp>CD</scp>319 for the identification of plasma cells in patients with clonal plasma cell diseases. Cytometry Part B - Clinical Cytometry, 2016, 90, 91-100.	0.7	47

#	Article	IF	Citations
19	CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features. Haematologica, 2011, 96, 328-332.	1.7	46
20	Introduction to the diagnosis and classification of monocyticâ€lineage leukemias by flow cytometry. Cytometry Part B - Clinical Cytometry, 2017, 92, 218-227.	0.7	44
21	Fluorochrome choices for multi-color flow cytometry. Journal of Immunological Methods, 2019, 475, 112618.	0.6	43
22	Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. Leukemia, 2020, 34, 589-603.	3.3	41
23	Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. Journal of Clinical Oncology, 2022, 40, 3151-3161.	0.8	40
24	EuroFlow Lymphoid Screening Tube (LST) data base for automated identification of blood lymphocyte subsets. Journal of Immunological Methods, 2019, 475, 112662.	0.6	35
25	STAT3 and STAT5B Mutations in T/NK-Cell Chronic Lymphoproliferative Disorders of Large Granular Lymphocytes (LGL): Association with Disease Features. Cancers, 2020, 12, 3508.	1.7	34
26	Optimization and testing of dried antibody tube: The EuroFlow LST and PIDOT tubes as examples. Journal of Immunological Methods, 2019, 475, 112287.	0.6	29
27	Flow cytometric immunobead assay for fast and easy detection of PMLâ€“RARA fusion proteins for the diagnosis of acute promyelocytic leukemia. Leukemia, 2012, 26, 1976-1985.	3.3	27
28	Frequent issues and lessons learned from EuroFlow QA. Journal of Immunological Methods, 2019, 475, 112520.	0.6	26
29	Standardization of 8-color flow cytometry across different flow cytometer instruments: A feasibility study in clinical laboratories in Switzerland. Journal of Immunological Methods, 2019, 475, 112348.	0.6	26
30	Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. Leukemia, 2020, 34, 3007-3018.	3.3	26
31	Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clinical Cancer Research, 2021, 27, 5195-5212.	3.2	26
32	Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia. British Journal of Haematology, 2006, 135, 43-51.	1.2	25
33	Comments on EuroFlow standard operating procedures for instrument setup and compensation for BD FACS Canto II, Navios and BD FACS Lyric instruments. Journal of Immunological Methods, 2019, 475, 112680.	0.6	24
34	Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay. Best Practice and Research in Clinical Haematology, 2010, 23, 333-345.	0.7	23
35	How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers. Journal of Immunological Methods, 2019, 475, 112388.	0.6	23
36	Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients. Blood, 2008, 111, 5130-5141.	0.6	22

#	Article	IF	Citations
37	Lot-to-lot stability of antibody reagents for flow cytometry. Journal of Immunological Methods, 2019, 475, 112294.	0.6	20
38	Expression profile of novel cell surface molecules on different subsets of human peripheral blood antigen-presenting cells. Clinical and Translational Immunology, 2016, 5, e100.	1.7	19
39	Detection of Circulating Tumor Plasma Cells in Monoclonal Gammopathies: Methods, Pathogenic Role, and Clinical Implications. Cancers, 2020, 12, 1499.	1.7	19
40	Impact of Next-Generation Flow (NGF) Minimal Residual Disease (MRD) Monitoring in Multiple Myeloma (MM): Results from the Pethema/GEM2012 Trial. Blood, 2017, 130, 905-905.	0.6	18
41	The Proliferation Index of Specific Bone Marrow Cell Compartments from Myelodysplastic Syndromes Is Associated with the Diagnostic and Patient Outcome. PLoS ONE, 2012, 7, e44321.	1.1	16
42	Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study. Modern Pathology, 2021, 34, 59-69.	2.9	15
43	Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. Haematologica, 2011, 96, 687-695.	1.7	13
44	Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma. Cancers, 2021, 13, 4924.	1.7	11
45	Immunophenotypic Analysis of Acute Megakaryoblastic Leukemia: A EuroFlow Study. Cancers, 2022, 14, 1583.	1.7	11
46	Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. Cancers, 2021, 13, 1454.	1.7	10
47	Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study. Blood Advances, 2021, , .	2.5	9
48	Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma. Archives of Pathology and Laboratory Medicine, 2022, 146, 862-871.	1.2	7
49	B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients. Cancers, 2021, 13, 1704.	1.7	6
50	Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics. Blood, 2018, 132, 112-112.	0.6	3
51	Impact of Pre-Analytical and Analytical Variables Associated with Sample Preparation on Flow Cytometric Stainings Obtained with EuroFlow Panels. Cancers, 2022, 14, 473.	1.7	3
52	Quality Assessment of a Large Multi-Center Flow Cytometric Dataset of Acute Myeloid Leukemia Patientsâ€"A EuroFlow Study. Cancers, 2022, 14, 2011.	1.7	3
53	Prognostic implications of MRD assessment in multiple myeloma patients: comparison of Next-Generation Sequencing and Next-Generation Flow. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e47.	0.2	2
54	Flow Cytometric Immunophenotyping as Diagnostic Tool of Hematopoietic Malignancies. Principles and Practice, 2012, , 143-160.	0.3	1

#	Article	IF	Citations
55	Impact of Treatment on B-Cell Regeneration By Next Generation Flow Cytometry in Patients with Multiple Myeloma. Blood, 2018, 132, 4491-4491.	0.6	1
56	Plasma Cell Disorders. , 0, , 235-250.		1
57	Circulating Tumor Cells (CTCs) for Comprehensive and Multiregional Non-Invasive Genetic Characterization of Multiple Myeloma (MM). Blood, 2019, 134, 3064-3064.	0.6	1
58	Circulating Tumor Cells (CTCs) for Comprehensive and Multiregional Non-Invasive Genetic Characterization of Multiple Myeloma (MM). Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e351.	0.2	0